Home » Newsletters » BioWorld Science

BioWorld Science

July 8, 2016

View Archived Issues

Syndax Pharmaceuticals and UCB enter exclusive worldwide license agreement for UCB-6352

Janssen Biotech exercises option within global license agreement with OSE Immunotherapeutics

Lysogene enrolls first patient in SAMOS study

First clinical data reported for novel ketolide WCK-4873

Positive topline results from phase IIb trial of vobarilizumab as monotherapy in RA

Bayer Healthcare develops Mnk1 inhibitors

ArmaGen signs collaboration with Rett Syndrome Research Trust

Forendo Pharma Oy patents 17beta-HSD1 inhibitors

Akarna Therapeutics discloses farnesoid X receptor agonists

Takeda Pharmaceutical presents GluN2B receptor inhibitors

Galderma Pharma divulges chemokine receptor antagonists

Rugen Holdings Cayman patent reports GluN2B antagonists

MicuRx Pharmaceuticals introduces antibacterial compounds

Seres Therapeutics begins phase Ib trial of microbiome therapeutic

CSI Laboratories launches a novel comprehensive PD-L1 expression assay

FDA issues complete response letter for Aggrastat in new STEMI indication

FDA grants fast track designation to idalopirdine

FDA approves Xolair for children with allergic asthma

Anti-apoE4 MAb 9D11 prevents beta-amyloid accumulation in vivo

Ribaxamase approved as generic name for Synthetic Biologics' SYN-004

Alnylam initiates phase I/II trial of ALN-HBV to treat chronic HBV infection

FDA places clinical hold on phase II ROCKET trial of JCAR-015 following patient deaths

TherapeuticsMD submits NDA for Yuvvexy for dyspareunia

GON4L identified as potential cancer biomarker and therapeutic target

Pivotal phase III data reported for deutetrabenazine in Huntington's disease

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 5, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...
Janssen Pharmaceutica reports new TMEM175 activators
BioWorld Science
Janssen Pharmaceutica NV has identified new endosomal/lysosomal proton channel TMEM175 activators that are potentially useful for the treatment of Parkinson’s...